TOKYO – News that Japanese pharma Daiichi Sankyo Group is pinning its growth strategy on oncology followed on the heels of the announcement that Daiichi and partner, U.S. firm Arqule Inc., are advancing their METIV-HCC study for tivantinib after achieving 60 percent of the target number of 500 patients with MET-high tumors in December.